Hepatocyte Necrosis Induced by Oxidative Stress and IL-1α Release Mediate Carcinogen-Induced Compensatory Proliferation and Liver Tumorigenesis  by Sakurai, Toshiharu et al.
Cancer Cell
ArticleHepatocyte Necrosis Induced by Oxidative Stress
and IL-1a Release Mediate Carcinogen-Induced
Compensatory Proliferation and Liver Tumorigenesis
Toshiharu Sakurai,1,3 Guobin He,1 Atsushi Matsuzawa,1 Guann-Yi Yu,1 Shin Maeda,4 Gary Hardiman,2
and Michael Karin1,*
1Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology and Department of Pathology
2Biomedical Genomics Microarray Facility (BIOGEM), Department of Medicine
School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
3Department of Clinical Molecular Biology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku,
Kyoto 606-8507, Japan
4Division of Gastroenterology, The Institute for Adult Disease, Asahi Life Foundation, 1-6-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan
*Correspondence: karinoffice@ucsd.edu
DOI 10.1016/j.ccr.2008.06.016SUMMARY
Hepatocyte IkB kinase b (IKKb) inhibits hepatocarcinogenesis by suppressing accumulation of reactive ox-
ygen species (ROS) and liver damage, whereas JNK1 activation promotes ROS accumulation, liver damage,
and carcinogenesis. We examined whether hepatocyte p38a, found to inhibit liver carcinogenesis, acts sim-
ilarly to IKKb in control of ROSmetabolism and cell death. Hepatocyte-specific p38a ablation enhanced ROS
accumulation and liver damage, which were prevented upon administration of an antioxidant. In addition to
elevated ROS accumulation, hepatocyte death, augmented by loss of either IKKb or p38a, was associated
with release of IL-1a. Inhibition of IL-1a action or ablation of its receptor inhibited carcinogen-induced
compensatory proliferation and liver tumorigenesis. IL-1a release by necrotic hepatocytes is therefore an
important mediator of liver tumorigenesis.INTRODUCTION
Themammalian liver is themajor drug-detoxifying organ, respon-
sible for metabolic activation and elimination of toxic chemicals
and metabolic intermediates (Liska, 1998). Many chemicals me-
tabolized in the liver also induce liver damage (Park et al.,
2005a) and increase the risk of hepatocellular carcinoma (HCC),
themost common type of liver cancer and the third leading cause
of cancer deathsworldwide (Thorgeirsson andGrisham, 2002). In
addition to toxic chemicals, major HCC risk factors include hep-
atitis B and C viruses (HBV and HCV), all of which cause chronic
liver injury and inflammation (Bosch et al., 2004). The US inci-
dence of HCC has been increasing rapidly due to the current
HCV epidemic, which together with ethanol consumption dra-
matically increases HCC risk (Yuan et al., 2004). HCC usually156 Cancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc.develops in the settingof chronic hepatitis or cirrhosis, conditions
that result in hepatocyte death and activation of resident liver
macrophages (Kupffer cells; KCs) and newly recruited inflamma-
tory cells. These conditions stimulate compensatory hepatocyte
proliferation, a response thatmaintains livermassbutmayalsobe
themain driver of hepatocarcinogenesis (Fausto, 1999). Although
the precise carcinogenic function of chronic liver inflammation
remains to be elucidated, results obtained in a mouse model in
which HCC is induced by the chemical procarcinogen diethyl-
nitrosamine (DEN) suggest that inflammation promotes hepato-
carcinogenesis through production of cytokines that stimulate
compensatory proliferation (Maeda et al., 2005; Naugler et al.,
2007). Enhanced hepatocyte turnover has also been observed in
HCV-linkedHCC(Ikedaetal., 1998;Ghanyetal., 2003).Suchresults
suggest that mechanisms that maintain hepatocyte viability andSIGNIFICANCE
Chronic liver injury and inflammation increase the risk of hepatocellular carcinoma (HCC), the third leading cause of cancer
deaths worldwide. How chronic liver injury enhances tumor development is not known. Previously, we found that loss of
hepatocyte IKKbmarkedly enhances carcinogen-induced liver injury and HCC development. Increased HCC development
was also seen in mice lacking hepatocyte p38a. We now show that loss of hepatocyte p38a or IKKb results in increased
accumulation of ROS and hepatocyte necrosis. We found that hepatocyte necrosis triggers the release of IL-1a, which
acts as a critical mediator of carcinogen-induced compensatory proliferation and HCC development. IL-1amay be a com-
mon tumor promoter produced in different forms of chronic liver injury and could be a target for tumor prevention.
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ROS, Necrosis, and IL-1a in Hepatocarcinogenesisprevent liver damage may reduce the risk of HCC. Indeed, hepa-
tocyte-specific expression of antiapoptotic Bcl-2 proteins pre-
vents HCC development (Pierce et al., 2002), although Bcl-2
promotes oncogenesis elsewhere (Korsmeyer, 1992).
Conversely, hepatocyte-specific ablation of IKKb, the catalytic
subunit of the IkB kinase (IKK) complex required for NF-kB acti-
vation (Rothwarf and Karin, 1999; Ghosh and Karin, 2002) and
prevention of hepatocyte death (Maeda et al., 2003), greatly
enhances DEN-induced hepatocarcinogenesis (Maeda et al.,
2005). Accelerated HCC development has also been observed
after hepatocyte-specific deletion of IKKg/NEMO, the regulatory
subunit of the IKK complex that is required for IKKb activation
(Rothwarf and Karin, 1999; Makris et al., 2000), even without
DEN exposure (Luedde et al., 2007). Increased HCC develop-
ment was also seen upon hepatocyte-specific ablation of p38a
(Hui et al., 2007). Like IKKb, p38a has antiapoptotic activity
(Park et al., 2002, 2005b). By contrast, inactivation of IKKb in my-
eloid cells inhibits compensatory proliferation and development
of DEN-induced HCC, even in mice lacking hepatocyte IKKb
(Maeda et al., 2005).
Important for induction of hepatocyte death are reactive
oxygen species (ROS), whose accumulation is prevented by
NF-kB-induced antioxidant proteins (Pham et al., 2004; Kamata
et al., 2005). Administration of the chemical antioxidant butylated
hydroxyanisole (BHA) to IkkbDhep mice, which lack hepatocyte
IKKb, prevents DEN-induced ROS accumulation and liver dam-
age, thereby attenuating HCC development (Maeda et al.,
2005). Hepatocyte IKKg/NEMO deficiency also increases ROS
accumulation, and its adverse effects are also reversed by BHA
(Luedde et al., 2007). Although it has not been examined whether
loss of hepatic p38a results in increased ROS accumulation after
carcinogenexposure, lossof p38a in fibroblasts augmentsoxida-
tive stress (Dolado et al., 2007). Exactly how hepatocyte death
promotes HCC development is not clear, but it has been pro-
posed that necrotic hepatocytes release factors (damage signals
or alarmins) that activate KCs, which in turn produce cytokines,
such as interleukin 6 (IL-6), that promote compensatory hepato-
cyteproliferation (Naugleret al., 2007). The identity of thealarmins
released by necrotic hepatocytes is not fully known, but it has
been proposed that one such factor is IL-1a (Chen et al., 2007).
We now show that, similar to IkkbDhep mice, mice lacking p38a
in hepatocytes (p38aDhep mice) also exhibit elevated ROS accu-
mulationafterDENexposure.Althoughp38aand IKKbcontroldif-
ferent antioxidant genes to prevent ROS accumulation, in both
casesBHA administration prevents hepatocyte damage and car-
cinogen-induced compensatory proliferation. Furthermore, we
demonstrate that the critical mediator that is released by necrotic
hepatocytes to stimulate compensatory proliferation and release
of procarcinogenic IL-6 is IL-1a. Interference with IL-1a signaling
or ablation of its receptor inhibits compensatory proliferation and
HCC induction.Wesuggest that IL-1a is a general protumorigenic
mediator that is released upon chronic liver damage.
RESULTS
Enhanced Hepatocarcinogenesis, Liver Damage,
and Compensatory Proliferation in p38aDhep Mice
We generated p38aDhep and p38aDL+H mice by crossing p38aF/F
mice (Nishida et al., 2004) with either Alb-Cre or Mx1-Cre mice,respectively. p38aDhep and p38aDL+H progeny were obtained in
the expected Mendelian ratio, were healthy, and did not show
any apparent liver dysfunction based on histomorphology and
serum levels of alanine aminotransferase (ALT) (data not shown).
Neither strain exhibited spontaneous liver tumors up to 1 year of
age, despite efficient ablation of p38a only in hepatocytes of
p38aDhep mice or in both hepatocytes and KCs of p38aDL+H
mice (see Figures S1A and S1B available online). However,
upon DEN injection on postnatal day 14 (Maeda et al., 2005),
p38aDhep mice exhibited elevated HCCmultiplicity and size rela-
tive to similarly treated p38aF/F controls (Figures 1A and 1B), as
previously reported for mice given DEN plus phenobarbital (Hui
et al., 2007). HCCs isolated from p38aDhep mice retained the
p38a deficiency but exhibited elevated c-Jun expression and
increased JNK activity (Figure 1C). In contrast, there was no sig-
nificant difference in HCC multiplicity between p38aDL+H and
p38aDF/F mice (Figure S1C). To rule out a contribution of Cre-in-
duced hepatocyte toxicity to the observed increase in tumor
Figure 1. Hepatocellular Carcinogenesis in p38aDhep Mice
(A) Livers of male p38aF/F (F/F) and p38aDhepmice 8months after DEN injection
(25 mg/kg).
(B) Tumor number (>0.5 mm) andmaximal tumor size (diameter in mm) in livers
of male p38aF/F (n = 15) and p38aDhep (n = 14) mice. Data are means ± SEM.
*p < 0.05 versus control mice.
(C) Loss of p38a enhances JNK activity and c-Jun expression in hepatocellular
carcinomas (HCCs). Lysates of microdissected HCCs (three separate sam-
ples) or nontumor liver tissue (Liver) from DEN-treated mice were analyzed
for JNK activity by immunocomplex kinase assay with GST-c-Jun as a sub-
strate. Lysates were also gel separated and analyzed by immunoblotting
with antibodies to the indicated proteins.
(D) Effects of p38a in hepatocytes and Kupffer cells on cytokine gene expres-
sion. Mice of the indicated genotypes were injected with DEN, and liver RNA
was extracted at the indicated times. Relative amounts of cytokine mRNAs
were determined by real-time qPCR and normalized to actin mRNA. The
amount of each cytokine mRNA in untreated liver was given an arbitrary value
of 1. Data are means ± SEM (n = 4).Cancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc. 157
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ROS, Necrosis, and IL-1a in Hepatocarcinogenesisload, we examined HCC induction in p38a+/F/Alb-Cre mice and
found no difference from p38aDF/F controls (Figure S1D).
Cytokine-driven compensatory proliferation has been sug-
gested to promote DEN-induced hepatocarcinogenesis (Maeda
et al., 2005; Naugler et al., 2007). Of the different cytokines in-
duced by DEN administration, a tumor-promoting role has been
shown for IL-6 (Naugler et al., 2007). Whereas deletion of p38a
only in hepatocytes augmented expression of IL-6 mRNA, de-
letion of p38a in both hepatocytes and KCs inhibited IL-6 pro-
duction (Figure 1D). A similar effect was seen for IL-1bmRNA at
4 hr and for HGF mRNA at 24 hr after DEN administration. No
obvious differences in TNFa and IL-1a mRNA amounts were
seen. Thus, in agreement with its previously documented role
in macrophages (Park et al., 2005b), p38a is also required for
induction of IL-6 mRNA in KCs, the main site of IL-6 expression
in DEN-treated liver (Maeda et al., 2005). Given the important
role of IL-6 in hepatocarcinogenesis (Naugler et al., 2007), its
reduced production in p38aDL+H mice can explain why these
mice do not exhibit the elevated hepatocarcinogenesis seen
in p38aDhep mice despite the absence of p38a in their hepato-
cytes. It should be noted, however, that using a different liver
carcinogenesis protocol that involves coadministration of
phenobarbital, Hui et al. (2007) found that absence of KC
Figure 2. Enhanced DEN-Induced Cell
Death, Compensatory Proliferation, and
JNK Activation in p38aDhep Mice
(A) ALT levels in serumwere determined 48 hr after
DEN injection.
(B–D) Extent of hepatocyte apoptosis (B), neutro-
phil infiltration (C), and compensatory proliferation
(D) was determined by TUNEL staining, MPO
assay (data show fluorescence intensity), or BrdU
labeling, respectively. Data are means ± SEM
(n = 4). *p < 0.05 versus control (F/F) mice.
(E) Mice were administered DEN as above, their
livers were isolated at the indicated times and ho-
mogenized, and JNK activity was determined by
immunocomplex kinase assay. Protein recovery
was determined by immunoblotting with JNK1
antibody. MKK4 and MKK7 phosphorylation was
analyzed by immunoblotting.
(F) Relative JNK activity in p38aF/F, p38aDhep, and
IkkbDhep mice after DEN injection. JNK activity in
untreatedp38aF/Fmicewas given an arbitrary value
of 1. Data aremeans ± SEM (n = 3). *p < 0.05 versus
control (F/F) mice.
(G) Expression of phospho-c-Jun in DEN-treated
livers. Cryosections of the indicated liver regions
before and after DEN injection were immuno-
stained with polyclonal phospho-c-Jun antibody.
Scale bar = 50 mm.
p38a had little further impact on tumor
load beyond the effect of hepatocyte
p38a deficiency. This may be due to re-
placement of IL-6 produced by KCs by
other tumor promoters induced by phe-
nobarbital.
The substantial increase in tumor load
in p38aDhep mice is similar that seen in
IkkbDhep mice (Maeda et al., 2005). Indeed, like IkkbDhep mice
(Maeda et al., 2005), p38aDhep mice exhibited more DEN-in-
duced liver damage as assessed by ALT release and hepatocyte
apoptosis asmeasured by TUNEL assay relative to controls (Fig-
ures 2A and 2B). Only a fraction of all hepatocytes undergo cell
death in response to a carcinogenic dose of DEN, and the loca-
tion of the dead cells parallels that of hepatocytes involved
in DEN metabolism (Yang et al., 1990). Histological analysis
confirmed more zone 3 hepatocyte necrosis in p38aDhep mice
2 days after DEN administration than in p38aF/F counterparts
(data not shown). p38aDhep mice also exhibited elevated neutro-
phil infiltration as measured by myeloperoxidase (MPO) activity
after DEN administration (Figure 2C). Due to their high regenera-
tive capacity, surviving hepatocytes undergo compensatory pro-
liferation and thereby maintain liver mass after liver damage
(Fausto et al., 2006). Labeling with bromodeoxyuridine (BrdU) re-
vealed more proliferating hepatocytes in p38aDhep mice after
DEN exposure (Figure 2D), located mainly around clusters of ap-
optotic cells in centrilobular lesions (data not shown). No differ-
ences in DEN-induced liver damage and compensatory prolifer-
ation between p38aF/F and p38a+/F/Alb-Cre mice were found
(Figure S1E), ruling out the possible contribution of Cre toxicity
to the observed phenotype.158 Cancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc.
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ROS, Necrosis, and IL-1a in HepatocarcinogenesisDeletion of IKKb in hepatocytes augments DEN-induced JNK
activation (Maeda et al., 2005), which contributes to enhanced
hepatocyte death, compensatory proliferation, and hepatocarci-
nogenesis (Sakurai et al., 2006). Absence of p38a also enhanced
and prolonged JNK activation (Hui et al., 2007; Figure 2E) but had
no substantial effect on IKK activation (Figure S2A). The increase
in JNK activity in DEN-injected p38aDhep mice was of higher
magnitude than in IkkbDhep mice (Figures 2E and 2F). Further-
more, p38aDhep mice exhibited increased activation of the JNK
kinases MKK4 and MKK7, an effect not seen in IkkbDhep mice
(Figure 2E). Immunohistochemical analysis revealed that JNK
activation detected by phosphorylation of c-Jun, a specific
JNK substrate (Hibi et al., 1993), mostly occurred in zone 3 hepa-
tocytes, the cells involved in DEN metabolism and ROS produc-
tion (Figure 2G). In both p38aDhep and IkkbDhep mice, administra-
tion of a JNK inhibitor inhibited DEN-induced liver damage and
compensatory proliferation (Figures S2B and S2C). Neither
loss of p38a nor loss of IKKb had a significant effect on ERK ac-
tivity after DEN treatment (Figure S2D). p38 phosphorylation also
did not differ between IkkbF/F and IkkbDhep mice (Figure S2E).
Enhanced ROS Accumulation in p38aDhep Mice
Accounts for Increased Liver Injury and Compensatory
Proliferation
A causal link between oxidative stress and cancer has been pro-
posed (Ames, 1983). Ablation of hepatocyte IKKb enhances ROS
accumulation after DEN injection (Kamata et al., 2005; Maeda
et al., 2005), and similar observations have beenmade in unchal-
lenged mice lacking hepatic IKKg/NEMO (Luedde et al., 2007).
We assessed accumulation of hepatocyte superoxides by
staining freshly frozen liver sections with dihydroethidine (DHE),
whose oxidation gives rise to the fluorescent derivative ethidine
(Veerman et al., 2004). More extensive fluorescence was seen in
centrilobular areas (zone 3), the site of DEN metabolism, 12 hr
after DEN administration in p38aDhep and IkkbDhep mice than in
matched controls (Figures 3A and 3B). We also detected in-
Figure 3. Enhanced ROS Accumulation in
p38aDhep and IkkbDhep Mice
(A and B) Liver cryosections prepared 12 hr after
DEN injection were incubated with 2 mMdihydroe-
thidine hydrochloride for 30 min at 37C. Cells
staining positive for the oxidized dye were identi-
fied by fluorescence microscopy (A) and quanti-
fied by image analysis software (B). Scale bar =
50 mm. Data are means ± SEM (n = 4). *p < 0.05
versus control (F/F) mice.
(C and D) Mice were fed either butylated hydro-
xyanisole (BHA)-supplemented (0.7%) or regular
chow for 2 days prior to DEN injection. After
48 hr, serum ALT was measured (C), the mice
were pulsed with BrdU, and proliferating cells
were identified by immunostaining (D). Data are
means ± SEM (n = 4). *p < 0.05.
creased accumulation of H2O2 in livers of
DEN-treated p38aDhep and IkkbDhep mice
using the ROS indicator 5-[and-6]-chloro-
methyl-20,70-dichlorodihydrofluorescein
diacetate (CM-H2DCFDA) (Figure S3). To
evaluate the contribution of oxidative stress to DEN-induced liver
damage, we placed a group of mice on a chow diet supple-
mented with the antioxidant BHA 2 days before DEN treatment.
Like IkkbDhep mice (Maeda et al., 2005), p38aDhep mice kept on
the BHA-supplemented diet showed a marked reduction in
DEN-induced liver injury (Figure 3C) and compensatory prolifer-
ation (Figure 3D). Thus, loss of either p38a or IKKb enhances
DEN-induced cell death and compensatory proliferation through
mechanisms that may depend on ROS accumulation.
IKKb and p38a Control Different Antioxidant Genes
In macrophages, p38a is required for induction of a subset of
NF-kB target genes, including the survival genes Pai2 and Bfl1
(Park et al., 2005b). To investigate whether hepatic p38a and
IKKb coregulate genes that inhibit ROS accumulation and main-
tain cell survival, we conducted expression profiling of p38aDhep,
IkkbDhep, and control livers 4 hr after DEN administration using
whole-genome arrays (Table S1; Figure S4). Data analysis re-
vealed changes in the expression of several genes relevant to
regulation of ROS accumulation, cell death, and cell prolifera-
tion. Curiously, very few of these genes were equally dependent
on both kinases. We confirmed increased expression of Fas,
E2F1,Gadd45b, and cyclinD1 (Ccnd1) and decreased expression
of p21waf1/cip1 and MKP2 by quantitative RT-PCR in p38aDhep
livers relative to controls (data not shown). In IkkbDhep livers,
cyclin D1 was also increased and MKP2 decreased relative to
control livers (Table S1).
Interestingly, p38aDhep livers exhibited a marked decrease
(2.5-fold) in expression of Hsp25 (heat shock protein 1) mRNA
relative to controls, a change not observed in IkkbDhep livers (Ta-
ble S1).We therefore examined the involvement of Hsp25 in ROS
accumulation in p38aDhep mice. DEN injection led to consider-
able Hsp25 protein accumulation by 8 hr in p38aF/F, but not in
p38aDhep, livers (Figure 4A). Defective Hsp25 mRNA induction
was specific to p38aDhep mice and was not seen in IkkbDhep
mice (Figure 4B). In contrast, IKKb, but not p38a, contributedCancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc. 159
Cancer Cell
ROS, Necrosis, and IL-1a in Hepatocarcinogenesisto DEN-induced SOD2 expression (data not shown; Maeda
et al., 2005). These experiments also confirmed that p38a abla-
tion enhanced expression of IRF1 mRNA and protein (Figures 4A
and 4B). We also found a difference in expression of heme oxy-
genase 1 (HO-1, also known as Hsp32), the inducible HO isoform
that provides protection against oxidative stress and inflamma-
Figure 4. Requirement of p38a for Hsp25 Expression
(A) Mice were injected with DEN, and their livers were isolated at the indicated
times and homogenized. Homogenates were gel separated and immunoblot-
ted with the indicated antibodies.
(B) Mice were treated as above, and total liver RNA was extracted 4 hr after
DEN injection. Amounts of mRNA relative to those in untreated p38aF/F livers
were determined by real-time qPCR. Data are means ± SEM (n = 4). *p < 0.05.
(C) Mice were injected with DEN, and their livers were isolated at the indicated
times, homogenized, and analyzed by immunoblotting as above.
(D–G) p38aDhep mice were infected with adenovirus expressing Hsp25 or
a control adenovirus 20 hr before DEN injection.
(D) Liver homogenates prepared 8 hr after DEN injection were analyzed by
immunoblotting (results from two different mice are shown).
(E) Liver cryosections prepared before and after DEN injection were incubated
with 2 mM dihydroethidine hydrochloride for 30 min at 37C. Cells staining
positive for the oxidized dye were identified by fluorescence microscopy.
Scale bar = 50 mm. The numbers at the bottom aremean fluorescence intensity
± SEM (n = 3).
(F) ALT levels in serumwere determined at the indicated times after DEN injec-
tion. Data are means ± SEM (n = 4). *p < 0.05 versus control.
(G) Compensatory proliferation was determined by BrdU labeling. Data are
means ± SEM (n = 4). *p < 0.05 versus control (F/F) mice.
(H) Liver homogenates prepared 48 hr after DEN injection were analyzed for
GSH content. Data are means ± SEM (n = 4). *p < 0.05 versus control (F/F)
mice.160 Cancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc.tion (Poss and Tonegawa, 1997). In p38aDhep mice, but not in
IkkbDhep mice (data not shown), HO-1 induction was attenuated
after DEN injection relative to p38aF/F mice (Figure 4C).
Hsp25 has been reported to inhibit ROS accumulation (Esco-
bedo et al., 2004; Garrido et al., 2006). To examine whether
Hsp25 also controls ROS accumulation in DEN-treated mice,
we constructed an adenovirus expressing Hsp25 and injected
it via the tail vein into p38aDhep mice. This restored liver Hsp25
expression (Figure 4D), lowered ROS accumulation (Figure 4E),
and reduced liver damage (Figure 4F) and compensatory pro-
liferation (Figure 4G) in DEN-injected mice. By contrast, adeno-
virus-mediated expression of IRF1 in liver enhanced ROS accu-
mulation and liver damage (Figure S5A). Hsp25 has been
proposed to inhibit ROS accumulation by increasing the concen-
tration of reduced glutathione (GSH) (Escobedo et al., 2004; Gar-
rido et al., 2006). Indeed, liver GSH content, which was lower in
p38aDhep relative to p38aF/F mice (Figure 4H), was restored upon
Hsp25 re-expression (Figure S5B).
ROS accumulation results in oxidative inhibition of MKPs,
leading to enhanced JNK activation that contributes to liver fail-
ure but can be prevented by BHA administration (Kamata et al.,
2005; Maeda et al., 2005). BHA administration partially inhibited
DEN-induced JNK activation in p38aDhep mice, but the effect
was less pronounced than in IkkbDhep mice, where BHA feeding
almost completely inhibited JNK activation (Figure 5A). Thus, en-
hanced ROS accumulation makes only a partial contribution to
JNK activation in p38aDhep mice. Consistent with this notion,
BHA had little effect, if any, on MKK4 activity (Figure 5B), which
was enhanced by loss of p38a but not IKKb (Figure 2E).
The microarray analysis revealed elevated Chop mRNA in
DEN-treatedp38aDhep liver (TableS1).Chop (C/EBPhomologous
protein) is a leucine-zipper transcription factor, also known as
growth arrest and DNA damage-inducible gene 153 (Gadd153),
that activates an apoptotic response downstream of ROS (Lai
and Wong, 2005). DEN injection into p38aF/F mice induced
Chop protein within 12 hr, and this response was augmented
in p38aDhep mice (Figure 5C). The amount of Chop mRNA was
significantly higher in DEN-treated p38aDhep livers than in p38aF/F
or IkkbDhep livers (Figure 5D). As expected for a gene whose
expression is induced upon ROS accumulation, induction of
Chop mRNA in DEN-treated p38aDhep mice was suppressed by
BHA, which had no effect on expression of Hsp25 mRNA
(Figure 5E), which acts upstream of ROS by inhibiting their accu-
mulation. Correspondingly, Hsp25 re-expression in p38aDhep liver
suppressed Chop expression (Figure 5F), whereas Chop expres-
sion was increased in livers of IRF1 adenovirus-infected mice
(Figure 5G).
IL-1a Release and Signaling Promote IL-6 Production,
Compensatory Proliferation, and Hepatocarcinogenesis
after Hepatocyte Death
We have proposed that an inflammatory response triggered by
hepatocyte death promotes compensatory proliferation and
HCC development by inducing KC production of IL-6 (Naugler
et al., 2007). Indeed, p38aDhep and IkkbDhep mice, which exhibit
more liver damage after DEN administration, produce more
IL-6 than control mice (Figure 1D; Maeda et al., 2005). DEN-in-
duced IL-6 production has been shown to depend on the adap-
tor protein MyD88, which is also required for liver carcinogenesis
Cancer Cell
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p38aDhep and IkkbDhep Mice
(A and B) Mice of the indicated genotypes were fed either
BHA-containing (0.7%) or regular chow for 2 days and then
injected with DEN.
(A) JNK activity was determined by immunocomplex kinase
assays of liver lysates prepared at the indicated times after
DEN injection.
(B) MKK4 phosphorylation was analyzed by immunoblotting.
(C) Mice were injected with DEN, their livers were isolated at
the indicated times and homogenized, and Chop expression
was examined by immunoblotting.
(D) Mice of the indicated genotypes were injected with DEN,
total liver RNA was extracted 4 or 10 hr later, and expression
of Chop mRNA was quantified. Data are means ± SEM (n = 4).
*p < 0.05 versus control (F/F) mice.
(E) p38aDhep mice were fed either BHA-supplemented (0.7%)
or regular chow (Cont.) for 2 days and then injected with
DEN. Total liver RNA was extracted 4 and 12 hr later, and ex-
pression of the indicated genes wasmeasured as above. Data
are means ± SEM (n = 4). *p < 0.05.
(F) p38aDhep mice were infected with adenovirus expressing
Hsp25 or a control adenovirus 20 hr before DEN injection.
Liver lysates prepared at the indicated times after DEN injec-
tion were analyzed for Chop expression.
(G) p38aF/F mice were infected with adenovirus expressing
IRF1 or a control adenovirus 20 hr before DEN injection. Liver
lysates prepared 8 hr after DEN injection were analyzed for
IRF1 and Chop expression.(Naugler et al., 2007). However, the receptor responsible for
DEN-induced MyD88 signaling was not identified. Recently, it
was shown that liver inflammation and failure caused by acet-
aminophen administration are mediated by IL-1a release from
necrotic cells and IL-1R activation (Chen et al., 2007). We there-
fore examinedwhether DEN-induced liver damage also results in
release of IL-1R ligands. In vitro, hepatocyte necrosis resulted in
extensive IL-1a, but not IL-1b or IL-6, release (Figure 6A; data not
shown). We collected venous blood through reverse perfusion of
the portal vein 4 hr after DEN administration and found higher
levels of IL-1a in p38aDhep and IkkbDhep mice than in control
mice (Figure 6B). Administration of BHA, which prevents hepato-
cyte death (Figure 3C), inhibited DEN-induced IL-1a release and
IL-6 production (Figure 6C), suggesting that they are both indeed
linked to oxidative stress and liver injury. Next, we examined
the role of IL-1R using Il1r/mice (Abcouwer et al., 1996). IL-1R
deficiency reduced DEN-induced IL-6 production to almost
the same extent as MyD88 deficiency (Figure 6D). Il1r/ mice
also exhibited less DEN-induced neutrophilic inflammation
(Figure 6E) and lower compensatory proliferation relative to
wild-type mice (Figure 6F). Reduced DEN-induced compensa-
tory proliferation in p38aDhep and IkkbDhep mice was also seen
upon administration of IL-1R antagonist (IL-1Ra, or anakinra),
which also reduced IL-6 production (Figure 6G). This experiment
provides further evidence that IL-6 production is dependent on
IL-1 signaling. Most importantly, Il1r/mice exhibited a marked
reduction in DEN-induced hepatocarcinogenesis (Figure 6H).
Consistent with the absence of IL-1b release by necrotic hepato-
cytes, mice lacking caspase-1, the enzyme required for the pro-
duction of mature IL-1b by macrophages (Greten et al., 2007),did not exhibit any defects in DEN-induced compensatory prolif-
eration (Figure S6).
DISCUSSION
Oxidative stress has been suggested to be amajor contributor to
cancer development (Ames, 1983) because it can exert many
protumorigenic effects, including altered gene expression (Allen
and Tresini, 2000), enhanced cell proliferation, and higher DNA
mutation rates (Toyokuni, 2006) as well as genomic instability
(Woo and Poon, 2004). However, the precise impact of oxidative
stress and antioxidant responses on tumor development is
poorly understood. NF-kB activation has been found to play
a critical role in preventing ROS accumulation through induction
of the antioxidants FHC and SOD2 (Pham et al., 2004; Kamata
et al., 2005; Sakon et al., 2003). Correspondingly, hepatocyte-
specific IKKb ablation, which prevents NF-kB activation (Maeda
et al., 2003), augments ROS accumulation in livers of mice ex-
posed to DEN and potentiates HCC development (Maeda
et al., 2005). Consequently, the antioxidant BHA prevents the in-
crease in HCC induction seen in IkkbDhep mice (Maeda et al.,
2005). BHA administration also prevents HCC formation in
mice lacking the IKKg/NEMO regulatory subunit (Luedde et al.,
2007). We now demonstrate that the p38a MAPK pathway also
prevents ROS accumulation and DEN-induced hepatocyte
death. As found for IkkbDhep mice, elevated susceptibility to liver
damage and increased carcinogen-induced compensatory pro-
liferation in p38aDhep mice are reversed by BHA administration.
Thus, increased ROS accumulation may be the main cause of
hepatocyte death in IKKb-, IKKg/NEMO-, and p38a-deficientCancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc. 161
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ROS, Necrosis, and IL-1a in HepatocarcinogenesisFigure 6. IL-1aRelease by Necrotic Hepatocytes and IL-1R Signaling Promote IL-6 Production, Compensatory Proliferation, and Hepatocar-
cinogenesis
(A) Concentrations of IL-1a and IL-1b in supernatants of live hepatocytes (no necrosis) and necrotic hepatocytes (13 106 cells per ml) lysed by one (13 necrosis)
or three (33 necrosis) cycles of freezing and thawing were measured by ELISA. Data are means ± SEM (n = 3).
(B) IL-1a in venous blood collected 4 hr after DEN injection was determined by ELISA. Data are means ± SEM (n = 4). *p < 0.05 versus control (F/F) mice.
(C) Mice were fed either BHA-supplemented (0.7%) or regular chow (Cont.) for 2 days prior to DEN injection. IL-1a and IL-6 in venous blood collected 4 hr after
DEN injection were measured by ELISA. Data are means ± SEM (n = 3). *p < 0.05 versus control.
(D) Roles of IL-1R and MyD88 in IL-6 induction. Mice were injected with DEN, and liver RNA was extracted at the indicated times. IL-6 mRNA was quantified by
real-time qPCR. Data are means ± SEM (n = 4). *p < 0.05 versus control mice.
(E and F) Effects of IL-1R ablation on inflammation and compensatory proliferation. Extent of neutrophil infiltration (E) and compensatory proliferation (F) was
determined by MPO assay (results show fluorescence intensity) and BrdU labeling, respectively, 48 hr after DEN injection. Data are means ± SEM (n = 4).
*p < 0.05 versus wild-type (WT) control mice.
(G) IL-1Ra (anakinra) inhibits compensatory proliferation and IL-6 production. PBS (control) or anakinra (1 g/kg/day) were administered for 2 days starting at the
time of DEN injection. Hepatocyte proliferation (upper panel) was measured by BrdU incorporation at 48 hr, while serum IL-6 (lower panel) was measured at 6 hr
after DEN administration. Data are means ± SEM (n = 3). *p < 0.05 versus control.
(H) Tumor multiplicity (>0.5 mm) and maximal tumor size (diameter in mm) in livers of male Il1r/ (n = 12) and WT (n = 14) mice. Data are means ± SEM. *p < 0.05
versus WT control mice.mice. Importantly, we found that DEN-induced hepatocyte death
results in the release of IL-1a and activation of IL-1R signaling,
leading to IL-6 induction and compensatory proliferation, pro-
cesses that are critical for hepatocarcinogenesis (Sakurai
et al., 2006; Naugler et al., 2007).
In the case of DEN, oxidative stressmainly affects centrilobular
(zone 3) hepatocytes, the cells in which DEN is metabolized via
a ROS-generating reaction (Yang et al., 1990). Both IkkbDhep
(Maeda et al., 2005) and p38aDhep mice accumulate more ROS
in these cells after DEN administration and exhibit more hepato-
cyte death than control mice. Yet neither IkkbDhep nor p38aDhep
mice exhibit spontaneous liver damage or HCC formation unless
challenged with a carcinogen. Although liver damage has been162 Cancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc.known to cause compensatory proliferation (Fausto et al.,
2006), which is enhanced in both IkkbDhep and p38aDhep mice,
the mechanism accounting for this response was not fully under-
stood. We now show that DEN-induced liver injury results in
rapid release of IL-1a, whose concentration in venous blood of
p38aDhep and IkkbDhep livers is significantly higher than in controls.
Most importantly, inhibition of IL-1R activation or its ablation in-
hibits DEN-induced IL-6 production, compensatory proliferation,
and/or hepatocarcinogenesis, processes that also depend on
MyD88 (Naugler et al., 2007), the adaptor protein that connects
IL-1R to downstream effector pathways (Akira et al., 2006). The
pathway initiated by hepatocyte death leading to compensatory
proliferation and liver tumor promotion is summarized in Figure 7.
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cinogenesis, IKKb and p38a use distinct mechanisms to prevent
ROS accumulation. In the case of IKKb and NF-kB, themost crit-
ical antioxidants are FHC (Pham et al., 2004) and SOD2 (Kamata
et al., 2005), but p38amainly acts via Hsp25, whose expression
is only marginally dependent on IKKb. Hsp25 is the mouse
homolog of human Hsp27, which is phosphorylated by MAP-
KAPK2/MK2 (Stokoe et al., 1992), a substrate for p38 MAPK
(Freshney et al., 1994). Curiously, in human HCCs, attenuated
Hsp27 phosphorylation correlates with tumor progression (Ya-
suda et al., 2005), but it is not clear whether this is due to de-
creased p38 activity. Hsp27 possesses antioxidant properties
associated with its ability to maintain reduced GSH and to neu-
tralize the toxic effects of oxidized proteins (Garrido et al., 2006).
Importantly, Hsp25 re-expression in p38aDhep livers increased
GSH concentration and reduced ROS accumulation, resulting
in less DEN-induced damage and compensatory proliferation.
DEN-challenged p38aDhep mice express more Chop than
p38aF/F mice. Chop has been described as a ROS-induced reg-
ulator of apoptosis (Lai and Wong, 2005), and its expression is
Figure 7. Control of ROS Accumulation, IL-1a Release, Hepatocyte
Death, Compensatory Proliferation, and Their Role in DEN-Induced
Hepatocarcinogenesis
p38a and IKKb use different mechanisms to prevent ROS accumulation and
excessive JNK activation, thereby maintaining hepatocyte survival and sup-
pressing liver injury. Whereas IKKb acts via NF-kB, which induces expression
of the antioxidants SOD2 and FHC, p38a upregulates expression of Hsp25,
which also prevents ROS accumulation and subsequent Chop induction. An-
other consequence of ROS accumulation is inhibition of MKPs, resulting in
prolonged JNK activation, which contributes to ROS accumulation and hepa-
tocyte death. p38a is also involved in the negative regulation of IRF1 expres-
sion and an as yet unidentified MKK4/7 kinase (MAP3K or MKKK). Increased
MKK4/7 activity contributes to elevated JNK activity, which promotes ROS
accumulation. All of these pathways control hepatocyte death, which results
in the release of IL-1a and activation of IL-1R/MyD88 signaling in Kupffer cells
(KC), leading to activation of IKKb and p38a, induction of IL-6 production,
stimulation of compensatory proliferation, and hepatocarcinogenesis.induced by different stresses, including oxidative stress (Oyado-
mari and Mori, 2004). Oxidative stress has been suggested to
induce Chop gene transcription through an AP-1 binding site
(Guyton et al., 1996), and the absence of p38a augments JNK
activation (Hui et al., 2007), which stimulates AP-1 transcriptional
activity (Karin, 1995) and also results in upregulation of c-Jun,
a critical component of AP-1 (Shaulian and Karin, 2002).
ROS accumulation also results in oxidative inhibition of MKPs,
the phosphatases responsible for termination of JNK activation,
and this is the major cause of enhanced JNK activation in IKKb-
deficient cells and mice (Kamata et al., 2005). Indeed, there is lit-
tle change in activation of the JNK kinases MKK4 and MKK7 in
IkkbDhep livers. However, MKP inactivation accounts for only
a part of the increase in JNK activity in p38aDhep mice, which ex-
hibit elevated MKK4/7 activity, an observation also made by Hui
et al. (2007). These findings suggest that p38a is involved in neg-
ative regulation of an as yet unidentified MKK kinase (MAP3K or
MKKK) that activates MKK4/7 (Figure 7). Both JNK1 activation
(Sakurai et al., 2006) and c-Jun expression (Eferl et al., 2003)
are important contributors to hepatocyte proliferation and HCC
development. Notably, sustained JNKactivation also contributes
to ROS accumulation (Ventura et al., 2004), thus explaining why
BHA, while not fully inhibiting excess JNK activation in p38aDhep
mice, still provides effective protection against liver damage. In
summary, p38a and IKKb negatively regulate ROS accumulation
and JNK activity through different mechanisms, all of which
maintain hepatocyte viability and suppress liver carcinogenesis
(Figure 7). Enhanced hepatocyte death caused by the absence
of either kinase results in increased IL-1a release, IL-1R activa-
tion, IL-6 production, and compensatory proliferation, which
eventually augments HCC development. Our results suggest
that the role of IL-1a release in chronic liver injury in patients suf-
fering from different forms of persistent hepatitis needs to be
evaluated. If IL-1a is also found tobe present in the injured human
liver, interference with IL-1R signaling may provide a highly spe-
cific and effective means of interfering with the most dreadful
consequence of chronic hepatitis, HCC development.
EXPERIMENTAL PROCEDURES
Animals, Tumor Induction, and Analysis
IkkbF/F, IkkbF/F:Alb-Cre (referred to as IkkbDhep), and p38aF/F mice were as de-
scribed previously (Maeda et al., 2003; Nishida et al., 2004). p38aDhep mice
were generated by crossing p38aF/F and Alb-Cre mice. p38aDL+H mice were
generated by treating p38aF/F:Mx1-Cremice with poly(IC) as described previ-
ously (Maeda et al., 2005). All mice were maintained in filter-topped cages on
autoclaved food and water at UCSD according to NIH guidelines, and all ex-
periments were performed in accordance with UCSD and NIH guidelines
and regulations. Fourteen-day-old mice and littermates on a C57BL/6 back-
ground were injected with 25 mg/kg DEN (Sigma). After 8 months on normal
chow, mice were sacrificed, and their livers were removed, separated into in-
dividual lobes, analyzed for presence of HCCs, and subjected to analysis of
histological and immunochemical parameters as described previously
(Sakurai et al., 2006). Hepatocytes were isolated and plated as described
previously (Leffert et al., 1979). Hepatocytes were cultured for 24 hr in arginine-
free medium containing 10% dialyzed serum to eliminate other cell types
(Leffert et al., 1979), and no KC contamination was detected by immunostain-
ing with antibodies against F4/80.
Collection of Venous Blood and IL-1a Measurement
We collected venous blood through reverse perfusion of the portal vein. After
clamping the inferior vena cava above the confluence of the hepatic vein, liversCancer Cell 14, 156–165, August 12, 2008 ª2008 Elsevier Inc. 163
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vena cava, and portal blood samples were used to measure cytokine concen-
tration. IL-1a and IL-1b were quantified by ELISA (R&D Systems) according to
the manufacturer’s instructions.
Biochemical and Immunochemical Analyses
JNK assays, real-time qPCR, immunoblotting, and immunohistochemistry
were as described previously (Sakurai et al., 2006). Antibodies used were
anti-phospho-MKK4, anti-phospho-MKK7, anti-phospho-ERK, anti-ERK1/2,
anti-phospho-p38, and anti-phospho-c-Jun (Cell Signaling Technology); anti-
Hsp27/25, anti-IRF1, anti-Chop, anti-c-Jun, anti-MKK4, anti-MKK7, anti-HO-1,
and anti-p38 (Santa Cruz Biotechnology); anti-JNK1 (PharMingen); anti-actin
(Sigma); and anti-IKKb (Upstate). Immunohistochemistry was performed using
an ABC staining kit (Vector Laboratories) according to the manufacturer’s
recommendations. To examine accumulation of superoxide anions or H2O2,
freshly prepared frozen liver sections were incubated with 2 mM dihydro-
ethidine hydrochloride (Invitrogen) or 5 mM 5-[and-6]-chloromethyl-20,70-di-
chlorodihydrofluorescein diacetate (CM-H2DCFDA; Invitrogen), respectively,
for 30 min at 37C, after which they were observed by fluorescence micros-
copy and quantified with MetaMorph software. Myeloperoxidase (MPO) activ-
ity was measured using an MPO activity assay kit (Invitrogen). Livers were
homogenized in MPO buffer (0.5% hexadecyl trimethyl ammonium bromide,
10 mM EDTA, 50 mM Na2HPO4 [pH 5.4]). GSH concentration was measured
as described previously (Kamata et al., 2005).
Microarray Analysis
Livers from p38aDhep, IkkbDhep, and corresponding floxed mice were removed
4 hr after DEN injection and lysed in TRIzol reagent (Invitrogen). Total RNAwas
extracted from livers using an RNeasy kit (QIAGEN). Biotinylated cRNA was
prepared using an RNA Amplification Kit (Ambion, catalog #1L1791) according
to the manufacturer’s directions. For microarray analysis, the IlluminaMouse 6
Sentrix Expression BeadChip was used (Illumina). Data analysis and quality
control were carried out using BeadStudio software (Illumina).
Adenoviral Transduction
Adenoviruses expressing IRF1 and Hsp25 were prepared as described pre-
viously (Iimuro et al., 1998). Adenovirus stocks were injected via the tail vein at
1 3 109 plaque-forming units per mouse. Before infection, virus stocks were
dialyzed against PBS containing 10% glycerol.
Statistical Analysis
Data are presented as means ± SEM. Differences were analyzed by Student’s
t test. p < 0.05 was considered significant.
ACCESSION NUMBERS
Array data have been deposited in the EBI ArrayExpress database (http://
www.ebi.ac.uk/microarray-as/ae/) with the accession number E-TABM-351.
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The Supplemental Data include six figures and one table and can be foundwith
this article online at http://www.cancercell.org/cgi/content/full/14/2/156/
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